Organogenesis (ORGO) CCO corrects insider grant and tax-share amounts

Rhea-AI Filing Summary

Organogenesis Holdings Inc. Chief Commercial Officer Brian Grow filed an amended insider transaction report. On February 18, 2026, he acquired 48,818 shares of Class A common stock at $0.00 per share through the vesting and settlement of a performance share award, and 11,887 shares were disposed of at $3.84 per share to cover tax obligations. After these adjustments, he directly owns 899,724 shares. The amendment corrects the previously reported share amounts related to this award, with no other changes.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Grow Brian

Role Chief Commercial Officer

Type	Security	Shares	Price	Value
Grant/Award	Class A Common Stock	48,818	$0.00	--
Tax Withholding	Class A Common Stock	11,887	$3.84	$46K

Holdings After Transaction: Class A Common Stock — 911,611 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Grow Brian

(Last) (First) (Middle)

C/O ORGANOGENESIS HOLDINGS INC.

85 DAN ROAD

(Street)

CANTON MA 02021

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Organogenesis Holdings Inc. [ ORGO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/18/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)
02/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	02/18/2026		A		48,818(1)	A	$0	911,611	D
Class A Common Stock	02/18/2026		F		11,887(1)	D	$3.84	899,724	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This Form 4 is being filed as an amendment to the Form 4 originally filed on February 20, 2026, to correct the number of shares reported as acquired upon the vesting and settlement of a performance share award and the number of shares reported as withheld in satisfaction of tax obligations in connection with such award. No other changes have been made to the original filing.

	/s/ William R. Kolb, Attorney-in-Fact	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Organogenesis (ORGO) report for Brian Grow?

Organogenesis reported that Chief Commercial Officer Brian Grow received a grant of 48,818 Class A common shares from a performance share award and had 11,887 shares withheld to satisfy tax obligations, all dated February 18, 2026, resulting in updated direct ownership of 899,724 shares.

Why was this Form 4/A amendment filed for Organogenesis (ORGO)?

The Form 4/A was filed to correct the number of shares previously reported as acquired on vesting of a performance share award and the number withheld for taxes. The amendment states no other changes were made to the original insider transaction report.

How many Organogenesis (ORGO) shares does Brian Grow own after the correction?

After the corrected transactions, Chief Commercial Officer Brian Grow directly owns 899,724 shares of Organogenesis Class A common stock. This figure reflects the updated grant amount and the shares withheld to cover tax obligations from the performance share award.

What was the nature of the share acquisition reported for Organogenesis (ORGO)?

The acquisition involved 48,818 shares of Class A common stock received at $0.00 per share through vesting and settlement of a performance share award. This is characterized as a grant or award acquisition, not an open-market purchase of Organogenesis shares.

How were taxes handled on Brian Grow’s Organogenesis (ORGO) share award?

To satisfy tax obligations from the performance share award, 11,887 shares of Organogenesis Class A common stock were disposed of at $3.84 per share. This tax-withholding disposition reduced the net shares delivered while leaving Grow with 899,724 directly owned shares.

Does the Organogenesis (ORGO) Form 4/A indicate any new transactions beyond corrections?

The Form 4/A states it only corrects the number of shares acquired on vesting and the shares withheld for taxes for the February 18, 2026 award. It explicitly notes that no other changes were made to the original insider filing.